13 results on '"Teo Vignoli"'
Search Results
2. Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA)
- Author
-
Pierluigi Allosio, Giovanni Addolorato, Fabio Caputo, Patrizia Balbinot, Davide Mioni, Doda Renzetti, Tiziana Fanucchi, Raffaella Rossin, Gianni Testino, Livia Maccio, Claudia Gandin, S. Arico, Michele Parisi, Maria Francesca Amendola, Aniello Baselice, Vincenzo Palmieri, Vito Campanile, Emanuele Scafato, Valentino Patussi, Mauro Bernardi, Giorgio Zoli, Cristina Meneguzzi, Teo Vignoli, Lisa Lungaro, Giovanni Greco, and Luigi C. Bottaro
- Subjects
medicine.medical_specialty ,Telemedicine ,Physiology ,medicine.medical_treatment ,Telehealth ,Alcohol use disorder ,Alcohol-related liver cirrhosis ,Alcohol-related liver disease ,ALD and SARS-CoV-2 ,Management of AUD ,SARS-CoV-2 infection ,Liver transplantation ,NO ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Internal medicine ,Pandemic ,medicine ,Humans ,Intensive care medicine ,Liver Diseases, Alcoholic ,Pandemics ,business.industry ,Gastroenterology ,COVID-19 ,Hepatology ,medicine.disease ,Alcoholism ,030220 oncology & carcinogenesis ,Communicable Disease Control ,Position paper ,Original Article ,030211 gastroenterology & hepatology ,business - Abstract
Background Coronavirus Disease 2019 (COVID-19), firstly reported in China last November 2019, became a global pandemic. It has been shown that periods of isolation may induce a spike in alcohol use disorder (AUD). In addition, alcohol-related liver disease (ALD) is the most common consequence of excessive alcohol consumption worldwide. Moreover, liver impairment has also been reported as a common manifestation of COVID-19. Aims The aim of our position paper was to consider some critical issues regarding the management of ALD in patients with AUD in the era of COVID-19. Methods A panel of experts of the Italian Society of Alcohology (SIA) met via “conference calls” during the lockdown period to draft the SIA’s criteria for the management of ALD in patients with COVID-19 as follows: (a) liver injury in patients with ALD and COVID-19 infection; (b) toxicity to the liver of the drugs currently tested to treat COVID-19 and the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) reorganization of the management of compensated and decompensated ALD and liver transplantation in the COVID-19 era. Results and Conclusions The COVID-19 pandemic has rapidly carried us toward a new governance scenario of AUD and ALD which necessarily requires an in-depth review of the management of these diseases with a new safe approach (management of out-patients and in-patients following new rules of safety, telemedicine, telehealth, call meetings with clinicians, nurses, patients, and caregivers) without losing the therapeutic efficacy of multidisciplinary treatment.
- Published
- 2021
3. Symptoms of protracted alcohol withdrawal in patients with alcohol use disorder: a comprehensive systematic review
- Author
-
Silvano Gallus, Alessandra Lugo, Elisa Borroni, Teo Vignoli, Lisa Lungaro, Giacomo Caio, Roberto De Giorgio, Giorgio Zoli, and Fabio Caputo
- Subjects
Pharmacology ,Psychiatry and Mental health ,Neurology ,Pharmacology (medical) ,Neurology (clinical) ,General Medicine - Abstract
Background: Alcohol withdrawal syndrome (AWS) is characterized by different phases (acute, early and protracted). Protracted alcohol withdrawal (PAW) presents some symptoms, which may persist for several weeks, months or even years after drinking cessation. Methods: We conducted a systematic review of the literature in major scientific databases on selected AWS symptoms (craving, sleep disorders, and anhedonia) in patients with alcohol use disorder. Results: Of the 102 eligible publications (70 RCTs and 32 cohort studies), 88 provided data on craving, 21 on sleep disorders, and 1 on anhedonia. Overall, 37 studies assessed craving using the Obsessive Compulsive Drinking Scale (OCDS). Pooled OCDS decreased from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month and 9.7 at 3 months. The corresponding estimates for treated individuals were 23.9, 18.8, 8.7, and 8.8, and for non-treated subjects, they were 25.3, 13.9, 13.2, and 11.4, respectively. In 4 studies assessing sleep disorders using the Epworth Sleeping Scale (ESS), the scale remained stable in time, i.e., 7.3 at baseline, 7.3 at 1 week, 7.2 at 1 month, and 7.1 at 3 months. Conclusions: This study confirms the presence of PAW after the resolution of the acute phase of AWS. The pharmacological approach to managing PAW may ensure a more rapid reduction of symptoms in three weeks. We highlight the importance of studying PAW and the ability of pharmacological treatment to reduce its symptoms. This review protocol is registered in Prospero (registration number: CRD42020211265). Summary: This systematic review summarizes literature on major symptoms of protracted alcohol withdrawal in patients with alcohol use disorder. The pharmacological approach to manage protracted alcohol withdrawal ensures a more rapid reduction of symptoms (craving in particular), achieving in three weeks similar results obtained only after almost 6 months without treatment.
- Published
- 2021
4. Alcohol use disorder in the COVID‐19 era: Position paper of the Italian Society on Alcohol (SIA)
- Author
-
S Arico, Lisa Lungaro, Tiziana Fanucchi, Raffaella Rossin, Cristina Meneguzzi, Gianni Testino, Teo Vignoli, Luigi C. Bottaro, Patrizia Balbinot, Emanuele Scafato, Doda Renzetti, Pierluigi Allosio, Vito Campanile, Valentino Patussi, Fabio Caputo, Giacomo Caio, Livia Maccio, Davide Mioni, Michele Parisi, Giorgio Zoli, Claudia Gandin, Maria Francesca Amendola, and Aniello Baselice
- Subjects
Liver Cirrhosis ,Medicine (miscellaneous) ,Disease ,Alcohol use disorder ,Telehealth ,Liver Cirrhosis, Alcoholic ,Recurrence ,Ambulatory Care ,Drug Interactions ,infections ,Social isolation ,Societies, Medical ,Alcoholics Anonymous ,media_common ,Alcoholic ,Telemedicine ,Alcoholism ,Psychiatry and Mental health ,COVID‐19 infection ,Italy ,Original Article ,Disease Susceptibility ,medicine.symptom ,medicine.medical_specialty ,COVID-19 Vaccines ,media_common.quotation_subject ,alcohol use disorder ,NO ,Medical ,Intervention (counseling) ,mental disorders ,medicine ,Humans ,Psychiatry ,Immunosuppression Therapy ,Pharmacology ,SARS-CoV-2 ,business.industry ,Addiction ,COVID-19 ,Original Articles ,medicine.disease ,COVID-19 Drug Treatment ,COVID-19 infection ,Liver Transplantation ,Communicable Disease Control ,Position paper ,Societies ,business ,Delivery of Health Care - Abstract
Coronavirus disease 2019 (COVID‐19) first emerged in China in November 2019. Most governments have responded to the COVID‐19 pandemic by imposing a lockdown. Some evidence suggests that a period of isolation might have led to a spike in alcohol misuse, and in the case of patients with alcohol use disorder (AUD), social isolation can favour lapse and relapse. The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in internal medicine, with appropriate tools to better manage patients with AUD and COVID‐19,considering some important topics: (a) the susceptibility of AUD patients to infection; (b) the pharmacological interaction between medications used to treat AUD and to treat COVID‐19; (c) the reorganization of the Centre for Alcohol Addiction Treatment for the management of AUD patients in the COVID‐19 era (group activities, telemedicine, outpatients treatment, alcohol‐related liver disease and liver transplantation, collecting samples); (d) AUD and SARS‐CoV‐2 vaccination. Telemedicine/telehealth will undoubtedly be useful/practical tools even though it remains at an elementary level; the contribution of the family and of caregivers in the management of AUD patients will play a significant role; the multidisciplinary intervention involving experts in the treatment of AUD with specialists in the treatment of COVID‐19 disease will need implementation. Thus, the COVID‐19 pandemic is rapidly leading addiction specialists towards a new governance scenario of AUD, which necessarily needs an in‐depth reconsideration, focusing attention on a safe approach in combination with the efficacy of treatment., All health care systems need to be reorganized during and after the COVID‐19 pandemic, and also the CAATs in order to combine operator safety with patient safety and care. The multi‐disciplinary intervention involving experts in the treatment of AUD and ALD with specialists in the treatment of COVID‐19 disease will need implementation and the contribution of the family and of care‐givers in the management of AUD and ALD patients will play a significant role.
- Published
- 2021
5. Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs
- Author
-
Francesco Giuseppe Foschi, Alberto Borghi, Alberto Grassi, Arianna Lanzi, Elvira Speranza, Teo Vignoli, Lucia Napoli, Deanna Olivoni, Michele Sanza, Edoardo Polidori, Giovanni Greco, Paolo Bassi, Francesco Cristini, Giorgio Ballardini, Mattia Altini, Fabio Conti, and on behalf of MITH Group
- Subjects
Drug ,medicine.medical_specialty ,Cirrhosis ,HCV microelimination ,media_common.quotation_subject ,Hepatitis C virus ,Population ,people who inject drugs ,medicine.disease_cause ,DIRECT ACTING ANTIVIRALS ,Article ,reinfection ,Internal medicine ,Health care ,medicine ,direct acting antivirals ,education ,Adverse effect ,media_common ,education.field_of_study ,drug users ,business.industry ,Incidence (epidemiology) ,General Medicine ,medicine.disease ,HCV treatment ,Medicine ,business - Abstract
Background: People who inject drugs (PWID) are the largest group at risk for HCV infection. Despite the direct acting antivirals (DAA) advancements, HCV elimination has been hindered by real-life difficulties in PWID. Aims: This study aimed to assess the impact of a multidisciplinary intervention strategy where HCV screening, treatment and follow-up were performed at the same location on efficacy and safety of DAA-therapy in real-life PWID population. Methods: All HCV-infected PWID referred to five specialized outpatient centers for drug addicts (SerDs) in Northern Italy were prospectively enrolled from May 2015 to December 2019. Hepatologists and SerDs healthcare workers collaborated together in the management of PWID inside the SerDs. Sustained virologic response (SVR), safety of treatment, proportion of patients lost to follow-up and reinfection rate were evaluated. Results: A total of 358 PWID started antiviral treatment. About 50% of patients had advanced fibrosis/cirrhosis, 69% received opioid substitution treatment, and 20.7% self-reported recent injecting use. SVR was achieved in 338 (94.4%) patients. Two patients died during treatment, one prematurely discontinued, resulting in a non-responder, twelve were lost during treatment/follow-up, and five relapsed. No serious adverse events were reported. SVR was lower in recent PWID than in former ones (89.2% vs. 95.8%, p = 0.028). Seven reinfections were detected, equating to an incidence of 1.25/100 person-years. Reinfection was associated with recent drug use (OR 11.07, 95%CI 2.10–58.38, p = 0.005). Conclusion: Our embedded treatment model could be appropriate to increase the linkage to care of HCV-infected PWID. In this setting, DAA regimens are well tolerated and highly effective, achieving a lower rate of reinfection.
- Published
- 2021
6. Alcohol-related chronic exocrine pancreatic insufficiency: diagnosis and therapeutic management. A proposal for treatment by the Italian Association for the Study of the Pancreas (AISP) and the Italian Society of Alcohology (SIA)
- Author
-
Raffaele, Pezzilli, Fabio, Caputo, Gianni, Testino, Valentino, Patussi, Giovanni, Greco, Livia, Macciò, Maria Raffaella, Rossin, Davide, Mioni, Patrizia, Balbinot, Claudia, Gandin, Francesca, Zanesini, Luca, Frulloni, Sarino, Aricò, Luigi C, Bottaro, Rinaldo, Pellicano, Emanuele, Scafato, and Teo, Vignoli
- Subjects
Male ,medicine.medical_specialty ,Pancreatitis, Alcoholic ,Antioxidants ,Naltrexone ,NO ,03 medical and health sciences ,Alcohol-induced disorders ,Chronic pancreatitis ,Alcoholic pancreatitis ,Exocrine pancreatic insufficiency ,Alcoholism ,Alcohol Abstinence ,Alcohol Deterrents ,Disease Management ,Disease Progression ,Enzyme Replacement Therapy ,Ethanol ,Exocrine Pancreatic Insufficiency ,Female ,Humans ,Life Style ,Oxidation-Reduction ,Pancreatic Neoplasms ,Psychotherapy ,Risk Factors ,Self-Help Groups ,0302 clinical medicine ,Internal medicine ,medicine ,Risk factor ,Nalmefene ,business.industry ,General Medicine ,Alcoholic ,medicine.disease ,medicine.anatomical_structure ,Acamprosate ,Pancreatitis ,030220 oncology & carcinogenesis ,Disulfiram ,030211 gastroenterology & hepatology ,business ,Pancreas ,medicine.drug - Abstract
Current estimates of the prevalence of chronic pancreatitis, one of the most common causes of exocrine pancreatic insufficiency, are in the range of 3-10 per 100,000 people in many parts of the world. Alcohol consumption is a very important risk factor for exocrine pancreatic insufficiency and is involved in nearly half of all cases. The main hypothesis regarding the role of chronic alcohol consumption in pancreatitis is that there must be additional environmental or genetic risk factors involved for ongoing damage to occur. Treatment of patients with alcohol-related exocrine pancreatic insufficiency is complex, as the patient has two concomitant pathologies, alcohol-use disorder (AUD) and exocrine pancreatic insufficiency/chronic pancreatitis. Alcohol abstinence is the starting point for treatment, although even this along with the most advanced therapies allow only a slowdown in progression rather than restoration of function. This position paper of the Italian Association for the Study of the Pancreas and the Italian Society of Alcohology provides an overview of the pathogenesis of alcohol-related pancreatitis and discuss diagnostic issues. Treatment options for both exocrine pancreatic insufficiency/chronic pancreatitis (with a focus on pancreatic enzyme replacement therapy) and AUD (acamprosate, disulfiram, oral naltrexone, long-acting injectable naltrexone, sodium oxybate, nalmefene, baclofen, and psychosocial interventions) are also reviewed.
- Published
- 2019
7. Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol
- Author
-
Gianni Testino, S Arico, Giovanni Greco, Doda Renzetti, Paolo Cimarosti, Michele Parisi, Maria Francesca Amendola, Livia Maccio, Pierluigi Allosio, Cristina Meneguzzi, Teo Vignoli, Fabio Caputo, Patrizia Balbinot, Roberta Agabio, Emanuele Scafato, Valentino Patussi, Vincenzo Palmieri, Tiziana Fanucchi, Raffaella Rossin, Valeria Zavan, and Davide Mioni
- Subjects
medicine.medical_specialty ,Acute alcohol intoxication ,Acute alcohol intoxication, Alcohol withdrawal syndrome, Pharmacological treatment ,Alcohol use disorder ,030204 cardiovascular system & hematology ,Tiapride ,NO ,law.invention ,Alcohol withdrawal syndrome ,03 medical and health sciences ,chemistry.chemical_compound ,Benzodiazepines ,0302 clinical medicine ,law ,Clomethiazole ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,Propofol ,Delirium tremens ,business.industry ,medicine.disease ,Tiapride Hydrochloride ,Intensive care unit ,Substance Withdrawal Syndrome ,chemistry ,Phenobarbital ,Emergency medicine ,Emergency Medicine ,Anticonvulsants ,business ,Sodium Oxybate ,Pharmacological treatment ,Alcoholic Intoxication ,Chlormethiazole ,medicine.drug - Abstract
The chronic use of alcohol can lead to the onset of an alcohol use disorder (AUD). About 50% of subjects with an AUD may develop alcohol withdrawal syndrome (AWS) when they reduce or discontinue their alcohol consumption and, in 3-5% of them, convulsions and delirium tremens (DTs), representing life-threatening complications, may occur. Unfortunately, few physicians are adequately trained in identifying and treating AWS. The Italian Society on Alcohol has, therefore, implemented a task force of specialists to draw up recommendations for the treatment of AWS with the following main results: (1) while mild AWS may not require treatment, moderate and severe AWS need to be pharmacologically treated; (2) out-patient treatment is appropriate in patients with mild or moderate AWS, while patients with severe AWS need to be treated as in-patients; (3) benzodiazepines, BDZs are the "gold standard" for the treatment of AWS and DTs; (4) alpha-2-agonists, beta-blockers, and neuroleptics may be used in association when BDZs do not completely resolve specific persisting symptoms of AWS; (5) in the case of a refractory form of DTs, the use of anaesthetic drugs (propofol and phenobarbital) in an intensive care unit is appropriate; (6) alternatively to BDZs, sodium oxybate, clomethiazole, and tiapride approved in some European Countries for the treatment of AWS may be employed for the treatment of moderate AWS; (7) anti-convulsants are not sufficient to suppress AWS, and they may be used only in association with BDZs for the treatment of refractory forms of convulsions in the course of AWS.
- Published
- 2018
8. Models of care for the management and treatment of hepatitis C virus infection among people who inject drugs
- Author
-
Alberto Borghi, D. Olivoni, Teo Vignoli, Fabio Conti, E. Polidori, M. Sanza, P. Bassi, F.G. Foschi, G. Greco, Vittoria Bevilacqua, and Arianna Lanzi
- Subjects
Hepatology ,business.industry ,Hepatitis C virus ,Gastroenterology ,Medicine ,business ,medicine.disease_cause ,Virology - Published
- 2019
9. Alcohol use disorder and GABA
- Author
-
Fabio, Caputo, Bianca Maria, Ciminelli, Carla, Jodice, Paola, Blasi, Teo, Vignoli, Mauro, Cibin, Giorgio, Zoli, and Patrizia, Malaspina
- Subjects
Adult ,Male ,Gene Frequency ,Italy ,Receptors, GABA-B ,Humans ,Female ,Middle Aged ,Alcohol-Related Disorders ,Polymorphism, Single Nucleotide ,Aged - Abstract
Alcohol use disorder (AUD) is a complex trait with genetic and environmental influences. Several gene variants have been associated with the risk for AUD, including genes encoding the sub-units of the γ-aminobutyric acid (GABA) receptors.This study evaluated whether specific single nucleotide polymorphisms (SNPs) in genes encoding GABASeventy-four AUD subjects and 128 Italian controls were genotyped for 10 SNPs in genes encoding GABA-B1 and GABA-B2 sub-units (GABBR1 and GABBR2). Allele, genotype, and haplotype frequencies were tested for the association with the AUD trait.A significant difference between AUD individuals and controls was observed at genotype level for rs2900512 of GABBR2 gene. The homozygous T/T genotype was not found in the controls, whereas it was over-represented in the AUD individuals. Under the recessive model (T/T vs C/T + C/C) this result was statistically significant, as well as the Odds Ratio for the association with the AUD trait.The results provide preliminary data on the association between GABA
- Published
- 2017
10. Neurobiological Evidence in Alcohol Addiction Can Help Pharmacological Treatment Personalization
- Author
-
Teo Vignoli, Elisa Martino, and Fabio Caputo
- Subjects
medicine.medical_specialty ,Alcohol addiction ,business.industry ,Medicine ,business ,Psychiatry ,Omics ,Pharmacological treatment ,Personalization - Published
- 2016
11. Neurobiological Evidence in Alcohol Addiction Can Help Pharmacological Treatment Personalization
- Author
-
Teo Vignoli and Elisa Martino
- Published
- 2016
12. P-28RISK OF RE-HOSPITALIZATION IN PATIENTS ATTENDING THE EMERGENCY DEPARTMENT FOR ACUTE ALCOHOL INTOXICATION: AN OBSERVATIONAL RETROSPECTIVE STUDY
- Author
-
Teo Vignoli, Fabio Caputo, Marco Domenicali, Maurizio Baldassarre, M. Cavazza, Alice Grignaschi, Mauro Bernardi, S. Guerrini, and Matteo Massimo Bossi
- Subjects
medicine.medical_specialty ,business.industry ,Retrospective cohort study ,General Medicine ,Emergency department ,Acute alcoholic intoxication ,Acute alcohol ,Re hospitalization ,Emergency medicine ,medicine ,In patient ,Observational study ,Intensive care medicine ,business - Abstract
Background. acute alcohol intoxication (AAI) is a frequent cause of admission to the emergency department (ED). Patients with several admission in ED because of AAI may present alcohol use disorders (AUDs) and therefore need specific evaluation and therapy. Aims. to identify factor associated to risk of readmission in ED for AAI patients. …
- Published
- 2015
13. GAMMA-HYDROXYBUTYRIC ACID PLUS NALTREXONE IN THE TREATMENT OF ALCOHOLICS RESISTANT TO MONO-THERAPY
- Author
-
Arfedele Del Re, Mauro Bernardi, F. Lorenzini, Teo Vignoli, Franco Trevisani, Giovanni Gasbarrini, Giovanni Addolorato, Giuseppe Francesco Stefanini, Pietro Andreone, and Fabio Caputo
- Subjects
Psychiatry and Mental health ,business.industry ,Medicine (miscellaneous) ,Medicine ,gamma-Hydroxybutyric acid ,Craving ,Withdrawal syndrome ,Pharmacology ,medicine.symptom ,Toxicology ,business ,Naltrexone ,medicine.drug - Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.